ScanScor WCFF Events
Total Events
862
Fish Alarms
324
Chart Now
373
UP / DOWN / UNCERTAIN
150 / 127 / 585
Max Repricing
97%
Max Fade Risk
99%
| Created | Ticker | Direction | Alarm | Type | Risk | Headline | Reason |
|---|---|---|---|---|---|---|---|
|
2026-06-05 23:36:38
Story: 2026-06-05 19:35:00
|
MNKD
ID 862
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 41% Fade: 74% Thesis Break: 18%
Today:
3.28 -
3.62
|
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Parse: PARSED
|
ADA data mostly extends prior Afrezza approval narrative, with supportive but non-pivotal analyses that may spark interest yet likely fade.
Input: ADEQUATE -
Enough context exists; key limitation is lack of detailed efficacy magnitude and whether any ADA presentation contains truly new market-moving data.
|
|
2026-06-05 23:34:20
Story: 2026-06-05 19:32:00
|
BMEA
ID 861
|
UP
Up 68% /
Down 32%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 72% Fade: 74% Thesis Break: 28%
Today:
1.22 -
1.48
|
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Parse: PARSED
|
Fresh ADA clinical updates and Phase I expansion can spark upside attention, but prior disclosure and microcap quality raise strong fade risk.
Input: ADEQUATE -
Enough price, short-interest, and recent-news context exists to judge this as actionable but likely promotional conference-driven news.
|
|
2026-06-05 23:34:14
Story: 2026-06-05 19:32:00
|
KLRA
ID 860
|
UNCERTAIN
Up 56% /
Down 44%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 62% Fade: 68% Thesis Break: 18%
Today:
18.80 -
21.40
|
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Parse: PARSED
|
ADA data extends prior topline and supports Phase 3, but conference-style clinical updates often spark only temporary biotech repricing.
Input: ADEQUATE -
Fresh clinical context is sufficient, though detailed efficacy tables and direct comparator framing would improve conviction.
|
|
2026-06-05 23:30:50
Story: 2026-06-05 19:30:00
|
DTIL
ID 859
|
UNCERTAIN
Up 4% /
Down 2%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 6% Fade: 88% Thesis Break: 3%
Today:
6.35 -
6.65
|
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
Parse: PARSED
|
This PR appears unrelated to DTIL and is conference-style biomarker publicity, not a concrete Precision BioSciences catalyst.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to dismiss immediate repricing relevance.
|
|
2026-06-05 20:32:23
Story: 2026-06-05 16:30:00
|
DBVT
ID 858
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
16.20 -
16.95
|
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Parse: PARSED
|
Conference participation is routine IR news with no disclosed data, regulatory milestone, financing, or partnership catalyst.
Input: ADEQUATE -
Story and recent context are sufficient to classify this as non-actionable routine conference news.
|
|
2026-06-05 20:31:11
Story: 2026-06-05 16:30:00
|
ORIC
ID 857
|
UNCERTAIN
Up 3% /
Down 7%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 2%
Today:
7.35 -
7.62
|
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine Nasdaq inducement grant disclosure is non-catalytic and unlikely to drive meaningful repricing despite elevated short interest.
Input: ADEQUATE -
News content is clear and repetitive versus prior inducement grant filings, with no financing, data, or regulatory catalyst.
|
|
2026-06-05 20:15:51
Story: 2026-06-05 16:15:00
|
NBTX
ID 856
|
UNCERTAIN
Up 3% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 2% Thesis Break: 4%
Today:
34.80 -
36.20
|
Voting Rights and Shares Capital of the Company
Parse: PARSED
|
Monthly voting-rights and share-capital notice is routine administrative disclosure, not a fresh catalyst beyond the already announced offering.
Input: ADEQUATE -
Story content is sufficient to classify this as non-actionable routine disclosure with minimal standalone repricing relevance.
|
|
2026-06-05 20:07:03
Story: 2026-06-05 16:05:00
|
VERA
ID 855
|
UNCERTAIN
Up 4% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
31.50 -
32.60
|
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grants for new hires are non-catalytic and usually do not change valuation or near-term clinical/regulatory odds.
Input: ADEQUATE -
News item is clear and repetitive versus prior inducement grant releases, with no new operational, clinical, or financing catalyst.
|
|
2026-06-05 20:06:53
Story: 2026-06-05 16:05:00
|
STTK
ID 854
|
UNCERTAIN
Up 46% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 58% Fade: 72% Thesis Break: 18%
Today:
4.25 -
4.85
|
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Parse: PARSED
|
Data presentation timing can spark anticipation repricing, but this is only an event announcement and likely vulnerable to pop-and-fade behavior.
Input: ADEQUATE -
Enough context exists to flag near-term chart attention, though actual Phase 1 data quality remains the key missing variable.
|
|
2026-06-05 20:06:45
Story: 2026-06-05 16:05:00
|
NTLA
ID 853
|
UNCERTAIN
Up 3% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 5% Fade: 85% Thesis Break: 2%
Today:
13.20 -
13.75
|
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grants for new hires are non-catalytic and rarely drive meaningful repricing in a liquid mid-cap biotech.
Input: ADEQUATE -
News item is clear and sufficient; no additional filings or clinical context are needed for this event-reaction assessment.
|
|
2026-06-05 20:03:24
Story: 2026-06-05 16:01:00
|
SYRE
ID 852
|
UNCERTAIN
Up 3% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 85% Thesis Break: 2%
Today:
72.00 -
74.50
|
Spyre Therapeutics Announces Grants of Inducement Awards
Parse: PARSED
|
Inducement option grants are routine hiring-related compensation news and rarely create meaningful standalone repricing in large clinical-stage biotech.
Input: ADEQUATE -
News item is clear and non-catalytic; recent clinical and financing context is sufficient to judge low urgency.
|
|
2026-06-05 20:03:17
Story: 2026-06-05 16:01:00
|
JBIO
ID 851
|
DOWN
Up 18% /
Down 78%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 72% Fade: 61% Thesis Break: 22%
Today:
15.75 -
17.25
|
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Parse: PARSED
|
Offering close confirms dilution and likely caps near-term upside despite stronger cash runway.
Input: ADEQUATE -
Recent financing sequence, price action, and company context are sufficient for a short-horizon event-reaction judgment.
|
|
2026-06-05 20:02:04
Story: 2026-06-05 16:00:00
|
ARQT
ID 850
|
UNCERTAIN
Up 3% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 5% Fade: 85% Thesis Break: 1%
Today:
20.90 -
21.40
|
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement RSU grant disclosure is non-catalytic, immaterial in size, and unlikely to drive meaningful repricing.
Input: ADEQUATE -
News context, liquidity, and recent company history are sufficient to classify this as routine non-actionable disclosure.
|
|
2026-06-05 16:23:16
Story: 2026-06-05 12:22:00
|
IPSC
ID 849
|
UNCERTAIN
Up 1% /
Down 2%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 1% Fade: 95% Thesis Break: 0%
Today:
2.00 -
2.06
|
Greenwood Village Gated Community Breaks Ground in Upscale Landmark District
Parse: PARSED
|
Story is unrelated real-estate PR noise and not a Century Therapeutics biotech catalyst.
Input: ADEQUATE -
Headline-source mismatch is clear enough to classify this as non-actionable ticker noise.
|
|
2026-06-05 15:49:16
Story: 2026-06-05 11:48:00
|
ENGN
ID 848
|
UNCERTAIN
Up 12% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 14% Fade: 88% Thesis Break: 10%
Today:
1.58 -
1.78
|
EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
Parse: PARSED
|
Award recognition is promotional, not new clinical, regulatory, financing, or partnership news, so repricing impact should be limited and fade-prone.
Input: ADEQUATE -
Story content is sufficient; it lacks concrete catalyst details beyond publicity and previously referenced development plans.
|
|
2026-06-05 13:30:37
Story: 2026-06-05 09:00:00
|
ABCL
ID 847
|
UNCERTAIN
Up 8% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
Business Wire
|
Reprice: 10% Fade: 78% Thesis Break: 3%
Today:
6.15 -
6.55
|
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
Parse: PARSED
|
Board appointment adds credibility but lacks a concrete operational catalyst likely to drive durable repricing.
Input: ADEQUATE -
News, price context, and recent catalyst history are sufficient to classify this as low-urgency routine governance news.
|
|
2026-06-05 13:21:58
Story: 2026-06-05 09:20:00
|
EDSA
ID 846
|
UP
Up 68% /
Down 32%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 74% Fade: 79% Thesis Break: 63%
Today:
6.40 -
8.60
|
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Parse: PARSED
|
Positive exploratory subgroup mortality data can spark biotech repricing, but non-prespecified analyses and prior promotion make any spike highly fade-prone.
Input: ADEQUATE -
Fresh headline, prior related news, market cap, liquidity, and price history are sufficient for an event-reaction judgment.
|
|
2026-06-05 13:01:11
Story: 2026-06-05 09:00:00
|
DSGN
ID 845
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 95% Thesis Break: 0%
Today:
10.40 -
10.90
|
S.A.F.E. Structure Designs Awarded U.S. Navy Contract for Submarine Torpedo Hatch Design, Engineering, and Manufacturing
Parse: PARSED
|
PR appears unrelated to Design Therapeutics and does not represent a biotech catalyst for DSGN.
Input: ADEQUATE -
Ticker-news mismatch is clear, making this non-actionable for DSGN despite fresh publication.
|
|
2026-06-05 12:02:55
Story: 2026-06-05 08:01:00
|
TSHA
ID 844
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 5%
Today:
5.65 -
6.05
|
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for new hires is recurring administrative news and lacks a concrete clinical, regulatory, or financing catalyst.
Input: ADEQUATE -
Recent headline history clearly shows repeated inducement-grant announcements, supporting low urgency classification.
|
|
2026-06-05 12:01:43
Story: 2026-06-05 08:00:00
|
URGN
ID 843
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 5%
Today:
26.80 -
28.20
|
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Inducement RSU grants for new hires are routine compensation news and rarely create meaningful standalone repricing in a $1.3B biotech.
Input: ADEQUATE -
Story is clear and recent context confirms this is non-catalyst compensation news, not a clinical or regulatory development.
|
|
2026-06-05 12:01:33
Story: 2026-06-05 08:00:00
|
BCDA
ID 842
|
UP
Up 74% /
Down 26%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
REGULATORY
GlobeNewswire RSS
|
Reprice: 81% Fade: 84% Thesis Break: 68%
Today:
0.84 -
1.18
|
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
Parse: PARSED
|
FDA minutes indicating one ongoing trial may support PMA is meaningful regulatory de-risking, but BCDA remains a fragile microcap with heavy fade risk.
Input: ADEQUATE -
News, balance-sheet weakness, prior related headlines, and price history are sufficient for a short-horizon event-reaction judgment.
|
|
2026-06-05 11:34:14
Story: 2026-06-05 07:32:00
|
CMND
ID 841
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 22% Fade: 88% Thesis Break: 76%
Today:
2.65 -
3.35
|
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Parse: PARSED
|
Webinar promotion repeats prior messaging and offers no new clinical data, regulatory action, financing change, or partnership catalyst.
Input: ADEQUATE -
Enough context shows this is scheduled investor-facing webinar news, not a fresh actionable catalyst.
|
|
2026-06-05 11:31:56
Story: 2026-06-05 07:30:00
|
GPCR
ID 840
|
DOWN
Up 3% /
Down 92%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 88% Fade: 28% Thesis Break: 12%
Today:
36.00 -
39.50
|
BlockchAIn Announces Pricing of $55 Million Public Offering of Common Stock
Parse: PARSED
|
Priced public offering is typically immediately dilutive and creates near-term downside repricing pressure around the deal price.
Input: ADEQUATE -
Story clearly describes a concrete financing catalyst with pricing, size, and expected closing timing.
|
|
2026-06-05 11:31:47
Story: 2026-06-05 07:30:00
|
KURA
ID 839
|
UNCERTAIN
Up 4% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
8.55 -
8.95
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Small inducement option grants for new hires are routine compensation disclosures and rarely create meaningful repricing in biotech.
Input: ADEQUATE -
News item is straightforward and non-catalytic; no additional filings or clinical context are needed for this event-reaction call.
|
|
2026-06-05 11:02:12
Story: 2026-06-05 07:00:00
|
MCRB
ID 838
|
UP
Up 68% /
Down 32%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
FINANCING
GlobeNewswire RSS
|
Reprice: 74% Fade: 71% Thesis Break: 58%
Today:
6.45 -
8.10
|
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Parse: PARSED
|
Cash runway extension and $25M non-dilutive Nestlé payment can spark relief repricing, though microcap quality and pending funding needs raise fade risk.
Input: ADEQUATE -
News, cash context, float, and recent deterioration are sufficient to assess a likely relief reaction with elevated fade risk.
|
|
2026-06-05 11:02:02
Story: 2026-06-05 07:00:00
|
TNGX
ID 837
|
UNCERTAIN
Up 4% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 78% Thesis Break: 2%
Today:
21.40 -
22.60
|
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for one new employee is non-catalytic and unlikely to change valuation or near-term clinical expectations.
Input: ADEQUATE -
Story is clear and recent context confirms this is a repeated administrative grant pattern, not a new business catalyst.
|
|
2026-06-05 11:01:56
Story: 2026-06-05 07:00:00
|
FHTX
ID 836
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 82% Thesis Break: 4%
Today:
3.60 -
3.88
|
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Parse: PARSED
|
Conference participation is routine and contains no new clinical, regulatory, financing, or partnership catalyst likely to drive meaningful repricing.
Input: ADEQUATE -
News and recent company context are sufficient to classify this as non-actionable routine investor-conference publicity.
|
|
2026-06-05 11:01:49
Story: 2026-06-05 07:00:00
|
CLYM
ID 835
|
UP
Up 63% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 58% Fade: 67% Thesis Break: 18%
Today:
10.35 -
11.85
|
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Parse: PARSED
|
Initial Phase 1 safety is supportive and advances the IgAN story, but conference-presented early healthy-volunteer data can spark only temporary repricing.
Input: ADEQUATE -
Fresh headline, prior presentation notice, price context, and financing backdrop are sufficient for an event-reaction judgment.
|
|
2026-06-05 11:01:42
Story: 2026-06-05 07:00:00
|
OCUL
ID 834
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 82% Thesis Break: 4%
Today:
8.45 -
8.95
|
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement grants for new hires are non-catalytic, repeated recently, and unlikely to drive durable repricing in OCUL.
Input: ADEQUATE -
News, price history, and recent context are sufficient to classify this as low-urgency routine corporate disclosure.
|
|
2026-06-05 11:00:33
Story: 2026-06-05 07:00:00
|
CPRX
ID 833
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 2% Fade: 0% Thesis Break: 0%
Today:
31.10 -
31.45
|
Catalyst Acoustics Group Promotes Jeremy Cantor to Group President
Parse: PARSED
|
This is unrelated executive promotion news for a different Catalyst entity, not a Catalyst Pharmaceuticals catalyst.
Input: ADEQUATE -
Ticker-news mismatch is clear, and no biotech-specific catalyst or CPRX fundamental change is disclosed.
|
|
2026-06-05 10:01:24
Story: 2026-06-05 06:00:00
|
SLDB
ID 832
|
UNCERTAIN
Up 18% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 22% Fade: 88% Thesis Break: 6%
Today:
6.95 -
7.55
|
Solidion Technology's 30+ Patents for Space-Based Artificial Intelligence Batteries Include the Highest-Performing Patented Lithium Anode Protection Technology
Parse: PARSED
|
Ticker-news mismatch and promotional patent PR without clinical, regulatory, financing, or partnership catalyst makes durable repricing unlikely.
Input: ADEQUATE -
Story references NASDAQ:STI, not SLDB, so this appears irrelevant to the provided biotech ticker.
|
|
2026-06-05 08:24:36
Story: 2026-06-05 04:23:00
|
SMMT
ID 831
|
UNCERTAIN
Up 6% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
14.40 -
15.10
|
Саммит AGP & DTx: цифровая терапия показывает снижение уровня HbA1c на 0,54% по мере того, как лечение диабета переходит от мониторинга к изменению
Parse: PARSED
|
Summit headline is unrelated to SMMT’s core oncology catalyst stack and appears to be mistaken ticker-matched routine conference publicity.
Input: ADEQUATE -
Recent context confirms this summit item already circulated and lacks company-specific, valuation-relevant SMMT catalyst content.
|
|
2026-06-05 08:00:34
Story: 2026-06-05 03:45:00
|
IMMP
ID 830
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 8%
Today:
0.37 -
0.41
|
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
Parse: PARSED
|
Repeat class-action solicitation after prior collapse is usually non-catalytic and adds little new repricing pressure.
Input: ADEQUATE -
Recent identical lawsuit headlines and prior trial-driven drawdown make this attorney PR low incremental value.
|
|
2026-06-05 08:00:23
Story: 2026-06-05 01:00:00
|
ADXN
ID 829
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 8% Thesis Break: 22%
Today:
6.30 -
6.85
|
Addex Convenes Annual General Meeting 2026
Parse: PARSED
|
AGM notice is routine, though proposed capital and conditional share increases add mild dilution overhang.
Input: ADEQUATE -
Story is clear and recent, and context is sufficient to classify it as low-urgency routine corporate news.
|
|
2026-06-04 23:01:14
Story: 2026-06-04 19:00:00
|
GPCR
ID 828
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 2% Fade: 0% Thesis Break: 0%
Today:
39.00 -
39.20
|
ECA LNG Phase 1 Achieves First LNG Production
Parse: PARSED
|
Story is about Sempra LNG operations, not Structure Therapeutics, so it is irrelevant to GPCR repricing.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to dismiss without further biotech or filing review.
|
|
2026-06-04 21:36:02
Story: 2026-06-04 17:34:00
|
FULC
ID 827
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 2% Fade: 95% Thesis Break: 0%
Today:
3.20 -
3.45
|
Fulcrum Venture Group Operating Advisor Nicholas Mirisis Elected Assistant Forum Officer of YPO Southern Sands Chapter for 2026-2027
Parse: PARSED
|
Leadership appointment at an unrelated Fulcrum Venture Group is non-catalytic and not actionable for Fulcrum Therapeutics.
Input: ADEQUATE -
Ticker-news mismatch is clear; no biotech catalyst, financing, regulatory, or clinical relevance to FULC.
|
|
2026-06-04 21:33:44
Story: 2026-06-04 17:33:00
|
IMMP
ID 826
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 96%
Today:
0.37 -
0.41
|
IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Parse: PARSED
|
Another plaintiff-law-firm alert repeats already-known trial failure and lawsuit overhang, adding little fresh repricing pressure after the prior 83% collapse.
Input: ADEQUATE -
Recent context clearly shows multiple similar lawsuit notices, making this item low-novelty and low-urgency.
|
|
2026-06-04 20:38:49
Story: 2026-06-04 16:37:00
|
TPST
ID 825
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 20%
Today:
1.24 -
1.36
|
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Parse: PARSED
|
Board appointments are routine governance news without clinical, financing, regulatory, or partnership substance to drive meaningful repricing.
Input: ADEQUATE -
News, balance-sheet stress, and recent catalyst history are sufficient to judge this as low-urgency routine corporate news.
|
|
2026-06-04 20:37:42
Story: 2026-06-04 16:37:00
|
INO
ID 824
|
DOWN
Up 8% /
Down 34%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 22% Fade: 88% Thesis Break: 41%
Today:
1.08 -
1.20
|
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
Parse: PARSED
|
Shareholder-law-firm investigation is usually derivative, backward-looking, and rarely creates durable repricing without new operational facts.
Input: ADEQUATE -
Story provides no new company disclosure beyond already alleged issues, so event value is limited.
|
|
2026-06-04 20:36:29
Story: 2026-06-04 16:36:00
|
RARE
ID 823
|
DOWN
Up 8% /
Down 28%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 85% Thesis Break: 22%
Today:
22.40 -
23.60
|
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Parse: PARSED
|
Shareholder-law-firm investigation headlines are usually derivative, backward-looking, and rarely create durable repricing without new company-disclosed facts.
Input: ADEQUATE -
Context shows similar lawsuit news already surfaced in March, reducing novelty and immediate catalyst value.
|
|
2026-06-04 20:32:56
Story: 2026-06-04 16:31:00
|
ELDN
ID 822
|
UNCERTAIN
Up 34% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 29% Fade: 78% Thesis Break: 12%
Today:
3.46 -
3.82
|
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Parse: PARSED
|
Conference presentation notice lacks new disclosed data and follows prior updated islet trial announcement, so immediate repricing odds look limited.
Input: ADEQUATE -
Enough context exists to judge this as a low-urgency abstract-style presentation announcement rather than a fresh catalyst.
|
|
2026-06-04 20:17:04
Story: 2026-06-04 16:15:00
|
LKFT
ID 821
|
UNCERTAIN
Up 58% /
Down 42%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 71% Fade: 63% Thesis Break: 34%
Today:
27.40 -
29.40
|
GILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN
Parse: PARSED
|
Deal close adds clinical asset, royalties, buyback capacity, and cash visibility, but much economics were previously announced and may partly be priced in.
Input: ADEQUATE -
Fresh closing details, economics, and capital allocation language are sufficient for event-reaction monitoring.
|
|
2026-06-04 20:16:56
Story: 2026-06-04 16:15:00
|
LKFT
ID 820
|
UP
Up 72% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 74% Fade: 41% Thesis Break: 24%
Today:
27.60 -
29.40
|
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Parse: PARSED
|
Deal close confirms major cash inflow, royalties, buyback capacity, and a clinical-stage autoimmune asset, creating credible near-term upside repricing attention.
Input: ADEQUATE -
Story is fresh and concrete, with enough financial and pipeline detail to assess immediate repricing risk.
|
|
2026-06-04 20:12:27
Story: 2026-06-04 16:10:00
|
BGMS
ID 819
|
UNCERTAIN
Up 38% /
Down 44%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
GlobeNewswire RSS
|
Reprice: 63% Fade: 86% Thesis Break: 78%
Today:
0.95 -
1.35
|
BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.
Parse: PARSED
|
All-stock acquisition of a private waste-energy asset may spark speculative attention, but dilution, closing risk, and microcap fragility make any pop highly fade-prone.
Input: ADEQUATE -
Need the exchange ratio, target financials, and S-4 details to judge dilution and whether the transaction is truly value-accretive.
|
|
2026-06-04 20:06:53
Story: 2026-06-04 16:05:00
|
GPCR
ID 818
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
FINANCING
GlobeNewswire RSS
|
Reprice: 2% Fade: 0% Thesis Break: 0%
Today:
36.53 -
39.74
|
Keel Infrastructure Announces Proposed Offering of $350 Million of Convertible Senior Notes
Parse: PARSED
|
Story is for KEEL, not GPCR, so it has no actionable repricing relevance for Structure Therapeutics.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to classify this as non-actionable for GPCR.
|
|
2026-06-04 20:06:34
Story: 2026-06-04 16:05:00
|
LYEL
ID 817
|
UNCERTAIN
Up 34% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 29% Fade: 78% Thesis Break: 14%
Today:
12.10 -
13.90
|
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Parse: PARSED
|
Conference presentation notice previews safety and translational data but lacks new efficacy results, making immediate repricing risk limited and fade-prone.
Input: ADEQUATE -
Enough context exists to judge this as a poster-announcement headline rather than a fresh data release.
|
|
2026-06-04 20:06:28
Story: 2026-06-04 16:05:00
|
MDGL
ID 816
|
UNCERTAIN
Up 3% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 8% Thesis Break: 1%
Today:
488.15 -
497.83
|
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for new hires is non-catalytic, tiny versus market cap, and recently repeated with no clear repricing signal.
Input: ADEQUATE -
News, price history, and recent context are sufficient to classify this as routine non-actionable corporate housekeeping.
|
|
2026-06-04 20:05:20
Story: 2026-06-04 16:05:00
|
AZTR
ID 815
|
DOWN
Up 8% /
Down 34%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
COMPLIANCE
PRNewswire RSS
|
Reprice: 18% Fade: 82% Thesis Break: 28%
Today:
0.20 -
0.23
|
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Parse: PARSED
|
Annual meeting adjournment for lack of quorum is weak governance/compliance noise, not a concrete business catalyst.
Input: ADEQUATE -
Story is clear and recent context shows this is a repeated adjournment-related update, limiting incremental signal.
|
|
2026-06-04 20:02:52
Story: 2026-06-04 16:01:00
|
PRAX
ID 814
|
UNCERTAIN
Up 6% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 9% Fade: 88% Thesis Break: 12%
Today:
258.00 -
272.00
|
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Parse: PARSED
|
Conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance to drive fresh repricing.
Input: ADEQUATE -
Context is sufficient; this appears to be standard investor-conference scheduling after recent material program news.
|
|
2026-06-04 20:02:45
Story: 2026-06-04 16:01:00
|
SNDX
ID 813
|
UNCERTAIN
Up 2% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 5% Fade: 90% Thesis Break: 3%
Today:
17.90 -
18.40
|
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement grant filing is non-catalytic, tiny versus float, and unlikely to drive meaningful repricing.
Input: ADEQUATE -
News context clearly shows this is a recurring administrative filing, not a fresh clinical, regulatory, or financing catalyst.
|
|
2026-06-04 19:31:07
Story: 2026-06-04 15:30:00
|
ERAS
ID 812
|
DOWN
Up 8% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 78%
Today:
12.90 -
13.80
|
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
Parse: PARSED
|
Law-firm investigation notice is stale, derivative of April IP dispute, and unlikely to create fresh standalone repricing.
Input: ADEQUATE -
Recent headline history clearly shows this is repeated legal-advertising noise, not a new company catalyst.
|
|
2026-06-04 18:47:18
Story: 2026-06-04 14:45:00
|
GPCR
ID 811
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 95% Thesis Break: 0%
Today:
38.50 -
39.80
|
S.A.F.E. Structure Designs Completes Critical U.S. Coast Guard Navigation Infrastructure Project at Southwest Pass
Parse: PARSED
|
Story appears unrelated to Structure Therapeutics and contains no biotech, clinical, regulatory, or financing catalyst for GPCR.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to dismiss without additional biotech context.
|
|
2026-06-04 18:47:10
Story: 2026-06-04 14:45:00
|
DSGN
ID 810
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 85% Thesis Break: 0%
Today:
10.45 -
10.75
|
S.A.F.E. Structure Designs Completes Critical U.S. Coast Guard Navigation Infrastructure Project at Southwest Pass
Parse: PARSED
|
Story appears unrelated to Design Therapeutics and contains no biotech catalyst, financing, regulatory, or clinical development relevance.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to dismiss without additional filings or clinical context.
|
|
2026-06-04 18:28:24
Story: 2026-06-04 14:27:00
|
VKTX
ID 809
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 1% Fade: 95% Thesis Break: 0%
Today:
29.70 -
29.95
|
Tampa Bay Physical Therapy Practice Sale Reflects Continued Demand for Established Healthcare Providers
Parse: PARSED
|
PR is unrelated to Viking Therapeutics and reflects ticker-name confusion, not a company catalyst.
Input: ADEQUATE -
Story clearly concerns Viking Mergers, not VKTX, so no biotech event signal is present.
|
|
2026-06-04 16:00:49
Story: 2026-06-04 12:00:00
|
JSPR
ID 808
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 0% Fade: 0% Thesis Break: 0%
Today:
0.53 -
0.54
|
A NEW ERA OF ALPINE LUXURY DEBUTS AT FAIRMONT JASPER PARK LODGE
Parse: PARSED
|
This PR is about a Canadian luxury resort and appears unrelated to Jasper Therapeutics.
Input: ADEQUATE -
Ticker-news mismatch is clear, so no biotech catalyst signal is present.
|
|
2026-06-04 15:16:05
Story: 2026-06-04 11:15:00
|
DSGN
ID 807
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 2% Fade: 95% Thesis Break: 0%
Today:
10.60 -
10.90
|
SCAD's New AI Insights Report Accelerates Creative Value
Parse: PARSED
|
Headline is unrelated to Design Therapeutics and contains no company-specific biotech catalyst, so repricing relevance is effectively nil.
Input: ADEQUATE -
News clearly appears misattributed to DSGN, allowing high-confidence dismissal without additional filings or clinical context.
|
|
2026-06-04 14:24:50
Story: 2026-06-04 10:23:00
|
DSGN
ID 806
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 1% Fade: 95% Thesis Break: 0%
Today:
10.40 -
10.70
|
Windy City Web Designs, Inc. Recognized as a WCBRB Best Businesses in America 2026 Honoree
Parse: PARSED
|
Press release appears unrelated to Design Therapeutics and contains no biotech, financial, regulatory, or clinical catalyst.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to classify this as non-actionable noise.
|
|
2026-06-04 14:05:15
Story: 2026-06-04 10:00:00
|
REGN
ID 805
|
UNCERTAIN
Up 5% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 95% Thesis Break: 10%
Today:
618.00 -
632.00
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Parse: PARSED
|
Law firm investigation notice is derivative of already digested trial-failure news and rarely creates fresh standalone repricing in large-cap biotech.
Input: ADEQUATE -
Story context clearly shows the material catalyst was the May 15 Phase 3 miss, not this follow-on legal advertisement.
|
|
2026-06-04 14:01:21
Story: 2026-06-04 10:00:00
|
ADMA
ID 804
|
DOWN
Up 8% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 88% Thesis Break: 72%
Today:
7.70 -
8.15
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Parse: PARSED
|
Repeat law-firm investigation headline adds little new information after prior short-report, downgrade, and guidance-withdrawal damage.
Input: ADEQUATE -
Recent identical headline and full catalyst timeline make this sufficient to judge as low incremental-news value.
|
|
2026-06-04 14:01:09
Story: 2026-06-04 10:00:00
|
ENGN
ID 803
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 96%
Today:
1.62 -
1.82
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Parse: PARSED
|
Law firm investigation is derivative of the May clinical collapse and usually adds little fresh repricing after an 80% drawdown.
Input: ADEQUATE -
Recent catalyst chain and price damage are clear enough to judge this as low-urgency follow-on legal headline noise.
|
|
2026-06-04 14:00:59
Story: 2026-06-04 10:00:00
|
TRDA
ID 802
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 88%
Today:
6.45 -
6.95
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Parse: PARSED
|
Class-action investigation alert is recycled, non-catalytic follow-on noise after the May clinical disappointment already repriced shares.
Input: ADEQUATE -
Recent headline history clearly shows this law-firm item is repetitive and not a fresh fundamental catalyst.
|
|
2026-06-04 13:31:22
Story: 2026-06-04 09:30:00
|
AKTX
ID 801
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 22% Fade: 88% Thesis Break: 20%
Today:
13.60 -
16.80
|
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Parse: PARSED
|
CEO-corner recap repeats recent preclinical ASCO themes without new data, deal, financing change, or regulatory catalyst.
Input: ADEQUATE -
Recent headline history clearly shows this is follow-on promotional commentary rather than a fresh catalyst.
|
|
2026-06-04 13:16:06
Story: 2026-06-04 09:15:00
|
LGVN
ID 800
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 14% Fade: 86% Thesis Break: 22%
Today:
0.75 -
0.86
|
Longeveron to Present at BIO International Convention 2026
Parse: PARSED
|
BIO convention presentation and partnership outreach are routine promotional updates without a signed deal, data release, or regulatory catalyst.
Input: ADEQUATE -
Context is sufficient; August HLHS topline remains the real catalyst, not this conference attendance announcement.
|
|
2026-06-04 13:05:02
Story: 2026-06-04 09:03:00
|
CPRX
ID 799
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
GlobeNewswire RSS
|
Reprice: 1% Fade: 0% Thesis Break: 0%
Today:
31.20 -
31.35
|
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Parse: PARSED
|
Story is about HCAT, not CPRX, so it should not drive Catalyst Pharmaceuticals repricing.
Input: ADEQUATE -
Ticker-news mismatch is clear and sufficient to dismiss event relevance.
|
|
2026-06-04 12:56:11
Story: 2026-06-04 08:55:00
|
AIM
ID 798
|
UNCERTAIN
Up 24% /
Down 31%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 18% Fade: 92% Thesis Break: 78%
Today:
0.66 -
0.82
|
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
Parse: PARSED
|
Investor video repackages prior Ebola preclinical claims without new data, funding, trial launch, partnership, or regulatory action.
Input: ADEQUATE -
News context and recent company releases clearly show this is promotional follow-up, not a fresh catalyst.
|
|
2026-06-04 12:49:27
Story: 2026-06-04 08:48:00
|
GRCE
ID 797
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 95% Thesis Break: 0%
Today:
2.40 -
2.52
|
Grace Hill Expands Occupant Experience Surveys to Support WELL Workplaces
Parse: PARSED
|
This appears unrelated ticker-noise about a real estate software company, not a biotech catalyst for Grace Therapeutics.
Input: ADEQUATE -
Ticker-company mismatch is clear, and no actionable biotech catalyst is present for GRCE.
|
|
2026-06-04 12:33:02
Story: 2026-06-04 08:30:00
|
FATE
ID 796
|
UNCERTAIN
Up 58% /
Down 42%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 61% Fade: 74% Thesis Break: 39%
Today:
2.08 -
2.55
|
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Parse: PARSED
|
Updated FT819 SLE data are encouraging, but this appears conference follow-through with prior disclosure overlap and likely volatile pop-and-fade behavior.
Input: ADEQUATE -
Enough context exists to judge this as actionable chart news, though detailed comparison versus prior FT819 datasets would improve conviction.
|
|
2026-06-04 12:32:55
Story: 2026-06-04 08:30:00
|
QNRX
ID 795
|
UP
Up 58% /
Down 42%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
REGULATORY
GlobeNewswire RSS
|
Reprice: 61% Fade: 82% Thesis Break: 71%
Today:
4.10 -
5.60
|
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Parse: PARSED
|
Japan orphan designation is a real regulatory milestone, but microcap fragility and repeated designation-style news make any spike highly fade-prone.
Input: ADEQUATE -
News, market cap, liquidity, and recent catalyst history are sufficient for a short-horizon event-reaction judgment.
|
|
2026-06-04 12:32:48
Story: 2026-06-04 08:30:00
|
RNXT
ID 794
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 14% Fade: 82% Thesis Break: 10%
Today:
0.87 -
0.96
|
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
Parse: PARSED
|
Conference presentation news mostly repeats known milestones and commercial commentary without a new catalyst, decision, data release, or financing change.
Input: ADEQUATE -
Enough context exists to classify this as routine investor-event news with limited immediate repricing relevance.
|
|
2026-06-04 12:31:27
Story: 2026-06-04 08:31:00
|
MTVA
ID 793
|
UNCERTAIN
Up 12% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 14% Fade: 88% Thesis Break: 6%
Today:
2.52 -
2.95
|
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
Parse: PARSED
|
Conference presentation notice lacks new data, deal, financing, or regulatory catalyst and closely repeats prior investor-event headlines.
Input: ADEQUATE -
News, price history, and recent headline context are sufficient to classify this as low-urgency routine event promotion.
|
|
2026-06-04 12:31:17
Story: 2026-06-04 08:30:00
|
SLDB
ID 792
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 1% Fade: 95% Thesis Break: 0%
Today:
6.70 -
6.95
|
SolidRun and Peridio Accelerate Development of Physical AI Deployments by Adding Avocado OS to RZ/V2N Vision AI Platforms
Parse: PARSED
|
Story is unrelated to Solid Biosciences and appears to be a ticker-name mismatch, not a biotech catalyst.
Input: ADEQUATE -
News clearly references SolidRun and Peridio hardware software, not SLDB's clinical, regulatory, financing, or corporate developments.
|
|
2026-06-04 12:03:56
Story: 2026-06-04 08:02:00
|
EBS
ID 791
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
7.70 -
8.10
|
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Parse: PARSED
|
Awareness-day sponsorship and advocacy messaging add no new sales, regulatory, clinical, or financing catalyst for EBS.
Input: ADEQUATE -
Story is clear and recent, but it is promotional and non-material versus prior disclosed naloxone positioning.
|
|
2026-06-04 12:03:49
Story: 2026-06-04 08:00:00
|
CELU
ID 790
|
UP
Up 62% /
Down 28%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
REGULATORY
GlobeNewswire RSS
|
Reprice: 71% Fade: 82% Thesis Break: 68%
Today:
0.95 -
1.28
|
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Parse: PARSED
|
Florida investigational-use access creates a new commercialization narrative, but weak fundamentals and promotional framing make any spike highly fade-prone.
Input: ADEQUATE -
News, balance-sheet stress, prior compliance issues, and microcap trading profile are sufficient for a short-window event-reaction assessment.
|
|
2026-06-04 12:03:42
Story: 2026-06-04 08:00:00
|
SPRY
ID 789
|
UNCERTAIN
Up 18% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 14% Fade: 82% Thesis Break: 6%
Today:
8.55 -
9.15
|
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
Parse: PARSED
|
Celebrity awareness collaboration is promotional, not a new clinical, regulatory, reimbursement, or financial catalyst likely to reprice SPRY materially.
Input: ADEQUATE -
Story details and company context are sufficient to classify this as low-urgency promotional news.
|
|
2026-06-04 12:02:16
Story: 2026-06-04 08:00:00
|
LPCN
ID 788
|
UNCERTAIN
Up 18% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 22% Fade: 82% Thesis Break: 12%
Today:
2.12 -
2.35
|
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Parse: PARSED
|
KOL event announcement rehashes prior Phase 3 discussion without new data, regulatory action, financing, or partnership catalyst.
Input: ADEQUATE -
News context and prior catalyst history are sufficient to classify this as low-urgency routine event promotion.
|
|
2026-06-04 12:02:03
Story: 2026-06-04 08:00:00
|
IMNN
ID 787
|
DOWN
Up 28% /
Down 72%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 79% Fade: 67% Thesis Break: 31%
Today:
1.75 -
2.45
|
IMUNON Announces Up to $10 Million Cash Financing
Parse: PARSED
|
Financing removes near-term cash risk but adds debt and likely dilution overhang for an $8M microcap, making downside repricing more likely.
Input: ADEQUATE -
Story, market cap, prior financing history, and recent clinical context are sufficient for a short-horizon event-reaction judgment.
|
|
2026-06-04 12:01:54
Story: 2026-06-04 08:00:00
|
ARVN
ID 786
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 22% Fade: 72% Thesis Break: 8%
Today:
7.45 -
8.10
|
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Parse: PARSED
|
Foundation program participation supports research visibility but adds no funding, data, regulatory decision, or near-term commercial catalyst.
Input: ADEQUATE -
Story context is sufficient; this appears non-material versus recent approval and pipeline milestones.
|
|
2026-06-04 12:01:46
Story: 2026-06-04 08:00:00
|
DARE
ID 785
|
UP
Up 68% /
Down 32%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
OTHER
GlobeNewswire RSS
|
Reprice: 71% Fade: 82% Thesis Break: 64%
Today:
1.95 -
2.55
|
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
Parse: PARSED
|
First product revenue is a real commercial milestone, but tiny-cap quality and OTC-style consumer launch dynamics raise strong pop-and-fade risk.
Input: ADEQUATE -
News, market cap, balance-sheet stress, and recent catalyst context are sufficient for a short-horizon event-reaction judgment.
|
|
2026-06-04 12:01:33
Story: 2026-06-04 08:00:00
|
IMMP
ID 784
|
UP
Up 72% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 76% Fade: 74% Thesis Break: 58%
Today:
0.39 -
0.52
|
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
Parse: PARSED
|
Positive first-in-human Phase I pharmacodynamic and safety data can spark upside attention, but microcap fragility and prior damage raise pop-and-fade risk.
Input: ADEQUATE -
Fresh data are concrete and actionable enough for event-reaction monitoring despite noisy litigation and prior program setbacks.
|
|
2026-06-04 11:45:43
Story: 2026-06-04 07:45:00
|
JAZZ
ID 783
|
UNCERTAIN
Up 18% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
PRNewswire RSS
|
Reprice: 20% Fade: 72% Thesis Break: 6%
Today:
227.00 -
234.00
|
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Parse: PARSED
|
Conference abstract announcement on marketed Xywav is supportive but lacks new disclosed efficacy, regulatory change, or clearly market-moving catalyst.
Input: ADEQUATE -
Enough context exists to judge this as routine conference-presentation news rather than a fresh repricing catalyst.
|
|
2026-06-04 11:33:35
Story: 2026-06-04 07:32:00
|
SPRC
ID 782
|
UNCERTAIN
Up 38% /
Down 34%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
GlobeNewswire RSS
|
Reprice: 41% Fade: 86% Thesis Break: 73%
Today:
8.20 -
11.80
|
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
Parse: PARSED
|
Acquisition closing is mostly previously telegraphed, strategically speculative, and may spark a low-float pop but lacks near-term clinical or revenue catalyst.
Input: ADEQUATE -
Recent related headlines show this closing was anticipated, reducing novelty despite microcap volatility and possible short-lived reaction.
|
|
2026-06-04 11:32:23
Story: 2026-06-04 07:30:00
|
PSTV
ID 781
|
UNCERTAIN
Up 38% /
Down 18%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
GlobeNewswire RSS
|
Reprice: 34% Fade: 78% Thesis Break: 22%
Today:
5.10 -
6.10
|
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
Parse: PARSED
|
CAP accreditation is commercially supportive but not a near-term revenue inflection, so any spike is likely modest and fade-prone.
Input: ADEQUATE -
News, market cap, float, short interest, and recent catalyst context are sufficient for an event-reaction judgment.
|
|
2026-06-04 11:32:16
Story: 2026-06-04 07:30:00
|
RZLT
ID 780
|
UNCERTAIN
Up 22% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 24% Fade: 82% Thesis Break: 12%
Today:
4.20 -
4.85
|
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Parse: PARSED
|
Conference presentation notice mostly repeats previously disclosed sunRIZE and program information, limiting fresh catalyst value after the recent upLIFT-driven move.
Input: ADEQUATE -
Enough context exists to judge this as non-novel conference news rather than a new clinical or regulatory catalyst.
|
|
2026-06-04 11:02:54
Story: 2026-06-04 07:00:00
|
INSM
ID 779
|
UNCERTAIN
Up 4% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 6% Fade: 12% Thesis Break: 3%
Today:
101.00 -
105.00
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grants for new hires are non-catalytic compensation disclosures and rarely drive meaningful repricing in large-cap biotech.
Input: ADEQUATE -
Story is clear and complete; no additional filings or clinical context are needed for this event-reaction assessment.
|
|
2026-06-04 11:02:45
Story: 2026-06-04 07:00:00
|
GHRS
ID 778
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 41% Fade: 72% Thesis Break: 18%
Today:
23.60 -
25.80
|
GH Research Announces Publication of Phase 2a Postpartum Depression Results
Parse: PARSED
|
Published small open-label PPD data and conference acceptances are supportive but mostly confirmatory after prior stronger TRD disclosures.
Input: ADEQUATE -
Enough context exists; main limitation is the tiny 10-patient open-label PPD dataset and already-public TRD strength.
|
|
2026-06-04 11:02:34
Story: 2026-06-04 07:00:00
|
LONA
ID 777
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 16% Fade: 82% Thesis Break: 8%
Today:
8.35 -
9.15
|
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
Parse: PARSED
|
Conference presentation reiterates prior Phase 1 and planned Phase 2 timing without new data, regulatory action, financing, or partnership catalyst.
Input: ADEQUATE -
Story context is sufficient; this appears promotional and repetitive versus recent meeting-participation news.
|
|
2026-06-04 11:02:28
Story: 2026-06-04 07:00:00
|
REGN
ID 776
|
UNCERTAIN
Up 28% /
Down 14%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 22% Fade: 61% Thesis Break: 8%
Today:
607.00 -
628.00
|
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Parse: PARSED
|
Conference-preview PR lacks actual data release or regulatory action, so immediate repricing odds are limited despite upcoming abstracts.
Input: ADEQUATE -
Enough context exists; this is a standard meeting-preview announcement without concrete results in the release.
|
|
2026-06-04 11:02:18
Story: 2026-06-04 07:00:00
|
SNDX
ID 775
|
DOWN
Up 18% /
Down 74%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 79% Fade: 31% Thesis Break: 28%
Today:
16.90 -
18.90
|
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Parse: PARSED
|
Convertible notes financing is typically near-term dilutive and pressures biotech shares despite extending cash runway.
Input: ADEQUATE -
News, balance-sheet context, short interest, and price history are sufficient for an event-reaction judgment.
|
|
2026-06-04 11:02:12
Story: 2026-06-04 07:00:00
|
BYSI
ID 774
|
DOWN
Up 18% /
Down 57%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
OTHER
GlobeNewswire RSS
|
Reprice: 46% Fade: 74% Thesis Break: 28%
Today:
1.52 -
1.88
|
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Parse: PARSED
|
Leadership transition without new clinical or financing catalyst can signal execution strain and funding overhang for a thinly traded microcap.
Input: ADEQUATE -
News, liquidity, recent catalyst context, and balance-sheet clues are sufficient for a short-horizon event-reaction assessment.
|
|
2026-06-04 11:02:05
Story: 2026-06-04 07:00:00
|
OCUL
ID 773
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 72% Thesis Break: 4%
Today:
8.10 -
8.55
|
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Parse: PARSED
|
Conference participation without new data, regulatory action, or partnership is routine and unlikely to drive meaningful repricing.
Input: ADEQUATE -
Story content is sufficient to classify this as non-catalytic conference news.
|
|
2026-06-04 11:01:59
Story: 2026-06-04 07:00:00
|
GUTS
ID 772
|
UP
Up 72% /
Down 28%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 74% Fade: 79% Thesis Break: 58%
Today:
0.70 -
0.98
|
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Parse: PARSED
|
Positive one-year obesity data is catalyst-relevant, but open-label small-sample results in a weak microcap carry high pop-and-fade risk.
Input: ADEQUATE -
Enough context exists to judge this as actionable chart news, though randomized comparator context would improve conviction.
|
|
2026-06-04 11:01:47
Story: 2026-06-04 07:00:00
|
OVID
ID 771
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
2.30 -
2.48
|
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance likely to reprice OVID now.
Input: ADEQUATE -
Story is clear and recent context confirms this is repetitive non-catalyst conference news.
|
|
2026-06-04 11:01:39
Story: 2026-06-04 07:00:00
|
AXSM
ID 770
|
UNCERTAIN
Up 28% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 8%
Today:
226.00 -
238.56
|
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Parse: PARSED
|
Conference-presented SYMBRAVO data lacks disclosed efficacy surprise, making this mostly routine promotional news after a strong run.
Input: ADEQUATE -
Headline and body do not provide substantive new data details or clear catalyst magnitude.
|
|
2026-06-04 11:01:32
Story: 2026-06-04 07:00:00
|
AEON
ID 769
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 41% Fade: 82% Thesis Break: 28%
Today:
0.69 -
0.86
|
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
Parse: PARSED
|
Poster data extends prior biosimilarity evidence, but conference presentation news in a tiny distressed microcap is more likely a temporary pop than durable repricing.
Input: ADEQUATE -
Recent FDA feedback, financing context, compliance risk, and prior analytical updates provide enough context to judge this as incremental rather than transformational.
|
|
2026-06-04 10:52:45
Story: 2026-06-04 06:52:00
|
SMMT
ID 768
|
UNCERTAIN
Up 4% /
Down 2%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 6% Fade: 85% Thesis Break: 1%
Today:
14.80 -
15.35
|
AGP & DTx Summit: Digital therapeutics show 0.54% HbA1c reduction as diabetes care moves from monitoring to change
Parse: PARSED
|
Story is unrelated to Summit Therapeutics and contains no company-specific catalyst, financing, regulatory event, or clinical update.
Input: ADEQUATE -
Ticker-news mismatch is clear enough to dismiss without further filings or clinical context.
|
|
2026-06-04 10:30:42
Story: 2026-06-04 06:30:00
|
TECH
ID 767
|
UNCERTAIN
Up 24% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
PARTNERSHIP
PRNewswire RSS
|
Reprice: 18% Fade: 72% Thesis Break: 8%
Today:
49.80 -
52.20
|
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
Parse: PARSED
|
Product workflow collaboration is commercially interesting but lacks disclosed revenue, orders, exclusivity, or material financial impact.
Input: ADEQUATE -
Story and market context are sufficient; this appears incremental marketing-oriented partnership news rather than a concrete catalyst.
|
|
2026-06-04 10:01:05
Story: 2026-06-04 06:00:00
|
SLDB
ID 766
|
UNCERTAIN
Up 28% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 34% Fade: 88% Thesis Break: 82%
Today:
6.56 -
7.35
|
Solidion Technology Unveils Patented Extreme-Climate Battery Technology Targeting Low Earth Orbit-Based Artificial Intelligence Data Centers, Lunar Economy, and Space
Parse: PARSED
|
Ticker-news mismatch and promotional battery-space PR lacks concrete contract, revenue, regulatory, or biotech catalyst relevance.
Input: ADEQUATE -
Story references Nasdaq:STI, not SLDB, so this item should not drive a Solid Biosciences event reaction.
|
|
2026-06-04 08:00:55
Story: 2026-06-04 04:00:00
|
GPCR
ID 765
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 95% Thesis Break: 0%
Today:
36.80 -
37.90
|
Infrastructure AI Unveils Revolutionary Agentic Security Strategy
Parse: PARSED
|
Story appears unrelated to GPCR biotech operations and lacks any company-specific catalyst, making material repricing risk negligible.
Input: ADEQUATE -
Headline-body mismatch is clear enough to classify as irrelevant noise for this ticker.
|
|
2026-06-04 08:00:40
Story: 2026-06-03 22:13:00
|
CELC
ID 764
|
DOWN
Up 12% /
Down 82%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 86% Fade: 58% Thesis Break: 41%
Today:
82.00 -
95.00
|
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Parse: PARSED
|
Upsized $500M convert after a major selloff signals financing overhang, likely pressuring shares despite improved liquidity and debt repayment.
Input: ADEQUATE -
Fresh financing terms, recent price collapse, and capital structure context are sufficient to assess near-term downside repricing risk.
|
|
2026-06-04 08:00:33
Story: 2026-06-04 01:00:00
|
PHAR
ID 763
|
UP
Up 68% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
GlobeNewswire RSS
|
Reprice: 61% Fade: 42% Thesis Break: 24%
Today:
12.00 -
13.10
|
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Parse: PARSED
|
FDA acceptance removes a key overhang after the CRL and sets a new October PDUFA, but this is incremental label expansion.
Input: ADEQUATE -
Story is fresh and concrete, with prior CRL context, PDUFA timing, and enough market data for event-reaction assessment.
|